129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_F727FC829A42
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
UNIL/CHUV
Title
129TiP: SAKK 16/14 - anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
Title of the conference
Lung Cancer Conference organisers, ESMO and IASLC.
Author(s)
Rothschild S.I., Zippelius A., Prince S.S., Gonzalez M., Weder W., Xyrafas A., Rusterholz C., Pless M.
ISBN
1556-1380 (Electronic)
ISSN-L
1556-0864
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
11
Pages
S112
Language
english
OAI-PMH
oai:serval.unil.ch:BIB_F727FC829A42
DOI
10.1016/S1556-0864(16)30242-8
Pubmed
27198270
Open Access
Yes
Create date
06/06/2016 16:26
Last modification date
20/08/2019 16:23
Usage data